Study of Novel Treatment Combinations in Patients With Lung Cancer

Inclusion Criteria

• Key Inclusion Criteria: All Substudies: - Histologically or cytologically documented non-small-cell lung cancer (NSCLC). - No known actionable genomic alterations for which targeted therapies are available. - Eastern cooperative oncology group (ECOG) performance status score of 0 or 1. - Measurable disease per response evaluation criteria in solid tumors. - Adequate hematologic and end-organ function. - Individuals of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception. Substudy 01: All Experimental arms - Stage IV NSCLC. - For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative. - PD-L1 status by central confirmation. - No prior systemic treatment for metastatic NSCLC. Substudy 02: All Experimental arms - Stage IV NSCLC. - In individuals with nonsquamous histology and actionable EGFR, ALK, or other known genomic alterations must have received treatment with at least 1 targeted therapy to the appropriate genomic alteration. Substudy 03: All Experimental arms - Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T[3-4]N2) NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8). - Planned surgery must comprise of lobectomy, sleeve lobectomy, or bi-lobectomy. - PD-L1 status by central confirmation. - For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative. Key Exclusion Criteria: All Substudies: - Mixed small-cell lung cancer and NSCLC histology. - Active second malignancy. - Active autoimmune disease. - History of or current non-infectious pneumonitis/interstitial lung disease. - Active serious infection within 4 weeks prior to study treatment. Substudy 01 and 02 - Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. - Received previous anticancer therapy within 4 weeks prior to enrollment. Substudy 03: All Experimental arms - NSCLC previously treated with systemic therapy or radiotherapy. - Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs). Note: Other protocol defined inclusion/exclusion criteria may apply